Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
Thakkar D, Hill B, Kositsky R, Tian S, Biral L, Russell V, Dave T, Love C, Roth C, McKinney M, Galal A, Neff J, Mian A, Kendall E, Ondrejka S, Chiaramonte M, Bhagat G, Ofori K, Reshef R, Kovach A, Sethi T, Mason E, Bhaskar S, Oluwole O, McCall C, Pallas C, Ghosh N, Ferdman R, Chen G, Hernandez-Ilizaliturri F, Zurko J, Cunningham A, Shah N, Hu B, Stephens D, Ghosh M, Bailey N, Patel K, Pagel J, Kannan K, Hsi E, Vaidya R, Ip A, Goy A, Kambhampati S, Ohgami R, Andreadis C, Gordillo C, Just B, Cohen J, Baim A, Barbello J, Cavallone E, Bachanova V, Laschen M, Teferra A, Lorcy F, Lamure S, Cartron G, Dardalhon V, Naresh K, Czader M, Reddy A, Thacker E, Parker C, Happ L, Dave S. Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL. Blood 2024, 144: 3409. DOI: 10.1182/blood-2024-199758.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCAR-T-cell-related encephalopathy syndromeProgression-free survivalCAR-T therapyDiffuse large B-cell lymphoma patientsActivated B-cell typeInternational Prognostic IndexChimeric antigen receptorCAR-TCytokine release syndromeOverall survivalFavorable prognosisPrognostic scoreB cellsAssociated with worse progression-free survivalAssociated with progression-free survivalSubtype of diffuse large B-cell lymphomaHigher International Prognostic IndexInternational Prognostic Index scoreAchievement of complete remissionLarge B-cell lymphomaTumors prior to treatmentSide effectsMultiple extranodal sitesSurface markers CD19
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply